This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Forward Step By Step With Action Plan 2016 - Continued Revenue Growth - Significant Pipeline Progress

HAMBURG, Germany, March 26, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) today reported financial results and corporate updates for the fiscal year ended 31 December 2012.
  • Growth trend continues

- Revenues +9% to € 87.3 m - Operating result adjusted € 1.4 m; net income € 2.5 m - Operating cash flow +18% to € 12.0 m - Strong and stable liquidity position of € 64.2 m - Expected revenues of € 90 m to € 100 m in 2013
  • Strong progress in all business units (EVT Execute /Integrate/Innovate) achieved

- Multiple new alliances and contract extensions (e.g. Bayer, CHDI and NIH) - Acceleration of EVT Innovate strategy through alliances with Harvard and Yale - Multiple milestones achieved with e.g. Andromeda/Teva, Boehringer Ingelheim, MedImmune, Novartis and Ono - Strategic alliance with 4-Antibody - Acquisition of CCS Cell Culture Service GmbH (after period-end)
  • Significant short- and mid-term pipeline catalysts

- DiaPep277 ®, positive Phase III results confirmed, data of second pivotal trial to come end of 2014 - Large Phase IIb trial started with EVT302 in Alzheimer`s Disease - Multiple clinical trials expected to start and read out in 2013/2014 (e.g. Phase II with EVT100 series in depression, several Phase I programmes in oncology, pain and other indications)

1. Operational performance – Good revenue growth, Milestones drive profitability

Revenue growth of 9%, operating result, R&D investments and liquidity in line with adjusted guidance

Evotec achieved continued profitable growth in 2012 with revenues up 9% to € 87.3 m (2011: € 80.1 m) and a net income of € 2.5 m (2011: € 6.7 m). The shift in revenues from milestones from Q4 2012 into 2013 had a negative effect on profitability, which as a result was lower than originally guided.

Growth in revenues was driven by the increase in revenues within the Company's drug discovery alliances and significant milestone payments through its collaborations in the amount of € 12.3 m (2011: € 10.5 m).

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs